CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors
15 Noviembre 2021 - 7:00AM
CoImmune, Inc., a clinical stage immuno-oncology company working to
redefine cancer treatment using best-in-class cellular
immunotherapies, today announced the appointment of Dr. Ed
Baracchini as chairman of the Company’s board of directors.
“As a member of the CoImmune board of directors,
Dr. Baracchini has provided strong counsel and guidance on many
important issues in corporate development and strategy,” stated Dr.
Charles Nicolette, chief executive officer. “In his new role as
chairman, his depth of experience in both biotechnology and
fundraising will provide new levels of insight and guidance as we
seek to advance our novel pipeline of cell-based immunotherapies
directed at severe diseases including acute lymphoblastic leukemia
and advanced renal cell carcinoma. We are also grateful to Dr.
Byung Geon Rhee for his service as chair of our board during a
formative period in the growth of CoImmune.”
Dr. Baracchini has extensive experience in
structuring and negotiating research and development partnerships,
mergers and acquisitions, and licensing agreements and has raised a
considerable amount of money in private and public capital markets.
He has personally negotiated more than 80 business transactions
with multinational pharmaceutical firms, biotechnology companies,
and prominent universities. He is currently a member of the board
of directors at INmune Bio (NASDAQ: INMB) and 4D Pharma (AIM: DDDD)
(NASDAQ: LBPS). From 2020-2021 he was chief business officer at
Imago Biosciences and from 2010 to 2018 he was chief business
officer at Xencor Inc. He has also held leadership roles in
business development and corporate strategy at Metabasis, Elitra
Pharmaceuticals, Warner-Lambert, Agouron Pharmaceuticals and Ionis
Pharmaceuticals. He earned his BS in microbiology at University of
Notre Dame, a PhD in molecular and cell biology at University of
Texas, and his MBA at University of California, Irvine.
“The Co-Immune CAR-CIK platform shows strong
potential to deliver a new generation of immune-oncology therapies
that offer significant advantages over earlier-generation CAR-T
therapies,” said Dr. Baracchini. “I look forward to continuing to
work with the outstanding board and management team at CoImmune as
we plan for many pivotal business and clinical development
milestones in the months and years ahead.”
About CoImmune, Inc.CoImmune is
a privately held, clinical stage immuno-oncology company that will
redefine cancer treatment using best-in-class cellular
immunotherapies. Our allogeneic CAR-CIK technology platform for
liquid and solid tumors is a variation on CAR-T therapy that
promises enhanced efficacy with greatly reduced toxicity. Our
autologous RNA-loaded dendritic cell technology for solid
tumors uses amplified total tumor mRNA to program highly
engineered dendritic cells to generate immune responses against
neoantigens without the need to identify them.
For more information visit www.coimmune.com
Investor Contact:Lori HarrelsonChief Financial
OfficerCoImmune, Inc.lharrelson@coimmune.comMedia
Contact:Adam DaleyBerry & Company Public
Relationsbberry@berrypr.com212.253.8881
4D Pharma (NASDAQ:LBPS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
4D Pharma (NASDAQ:LBPS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about 4D Pharma PLC (NASDAQ): 0 recent articles
Más de Artículos de Noticias